person · Reporting owner
Kestenberg-Messina Kaitlin M.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADMA BIOLOGICS, INC.ADMA · Entity 4477 | COO and SVP, Compliance | July 24, 2026 | July 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADMA BIOLOGICS, INC.
Report date July 24, 2026 · Filed July 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 443,061 |
Reported balance
After 2026-07-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-24 · Tax withholding · Disposed 3,177 · Balance 443,061 F1: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon the non-reportable vesting and settlement of restricted stock units ("RSUs"). This is not an open market sale of securities. F2: Includes, as of the transaction date, (i) 91,631 unvested RSUs out of 91,631 RSUs granted on February 9, 2026, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 58,338 unvested RSUs out of 77,784 RSUs granted on February 19, 2025, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 96,160 unvested RSUs out of 192,320 RSUs granted on April 1, 2024, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; F3: (continued from footnote 2) (iv) 7,500 unvested RSUs out of 30,000 RSUs granted on July 24, 2023, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (v) 23,750 unvested RSUs out of 95,000 RSUs granted on March 6, 2023, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 165,682 shares of common stock directly owned by the Reporting Person, which reflects prior option exercises and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Each RSU represents a contingent right to receive one share of common stock of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon the non-reportable vesting and settlement of restricted stock units ("RSUs"). This is not an open market sale of securities.
F2: Includes, as of the transaction date, (i) 91,631 unvested RSUs out of 91,631 RSUs granted on February 9, 2026, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 58,338 unvested RSUs out of 77,784 RSUs granted on February 19, 2025, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 96,160 unvested RSUs out of 192,320 RSUs granted on April 1, 2024, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
F3: (continued from footnote 2) (iv) 7,500 unvested RSUs out of 30,000 RSUs granted on July 24, 2023, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (v) 23,750 unvested RSUs out of 95,000 RSUs granted on March 6, 2023, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 165,682 shares of common stock directly owned by the Reporting Person, which reflects prior option exercises and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 24, 2026 Filed Jul 29, 2026 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 3,177 | $8.37 | $26,591.49 |
DisclosureSEC source: 0001140361-26-029923 · form4.xml · nonDerivative · entry 1 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 443,061 F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon the non-reportable vesting and settlement of restricted stock units ("RSUs"). This is not an open market sale of securities. F2 · balance_after: Includes, as of the transaction date, (i) 91,631 unvested RSUs out of 91,631 RSUs granted on February 9, 2026, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 58,338 unvested RSUs out of 77,784 RSUs granted on February 19, 2025, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 96,160 unvested RSUs out of 192,320 RSUs granted on April 1, 2024, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; F3 · balance_after: (continued from footnote 2) (iv) 7,500 unvested RSUs out of 30,000 RSUs granted on July 24, 2023, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (v) 23,750 unvested RSUs out of 95,000 RSUs granted on March 6, 2023, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 165,682 shares of common stock directly owned by the Reporting Person, which reflects prior option exercises and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| April 01, 2026 Filed Apr 4, 2026 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 20,362 | $9.11 | $185,497.82 |
DisclosureSEC source: 0001140361-26-013206 · form4.xml · nonDerivative · entry 1 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 446,238 F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities. F2 · balance_after: Includes, as of the transaction date (i) 91,631 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 58,338 unvested RSUs out of 77,784 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 96,160 unvested RSUs out of 192,320 RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; F3 · balance_after: (continued from footnote 2) (iv) 15,000 unvested RSUs out of 30,000 RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; (v) 23,750 unvested RSUs out of 95,000 RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; and (vi) 161,359 shares of common stock directly owned by the Reporting Person, which reflects prior option exercises and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionStock Option (right to buy) · Derivative | 2,175 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001140361-26-008905 · form4.xml · derivative · entry 14 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,825 Underlying: Common Stock · 2,175 shares Expires 2031-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The incentive stock options were granted to the Reporting Person on July 19, 2021, and are fully vested. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionStock Option (right to buy) · Derivative | 1,525 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001140361-26-008905 · form4.xml · derivative · entry 13 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,225 Underlying: Common Stock · 1,525 shares Expires 2031-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The incentive stock options were granted to the Reporting Person on February 25, 2021, and are fully vested. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionStock Option (right to buy) · Derivative | 2,646 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001140361-26-008905 · form4.xml · derivative · entry 12 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,771 Underlying: Common Stock · 2,646 shares Expires 2030-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The incentive stock options were granted to the Reporting Person on August 19, 2020, and are fully vested. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionStock Option (right to buy) · Derivative | 1,250 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001140361-26-008905 · form4.xml · derivative · entry 11 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires 2029-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The incentive stock options were granted to the Reporting Person on June 5, 2019, and are fully vested. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001140361-26-008905 · form4.xml · derivative · entry 10 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The incentive stock options were granted to the Reporting Person on February 14, 2017, and are fully vested. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | SaleCommon Stock | 10,096 | $15.63 | $157,800.48 |
DisclosureSEC source: 0001140361-26-008905 · form4.xml · nonDerivative · entry 9 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 466,600 F3 · shares: The securities were sold by the Reporting Person in accordance with the terms of the Divorce Settlement. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.59 to $15.65, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F5 · balance_after: Includes, as of the transaction date (i) 91,631 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 58,338 unvested RSUs out of 77,784 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 144,240 unvested RSUs out of 192,320 RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; F6 · balance_after: (continued from footnote 5) (iv) 15,000 unvested RSUs out of 30,000 RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; (v) 23,750 unvested RSUs out of 95,000 RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; and (vi) 133,641 shares of common stock directly owned by the Reporting Person, which reflects prior option exercises and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 2,175 | $1.55 | $3,371.25 |
DisclosureSEC source: 0001140361-26-008905 · form4.xml · nonDerivative · entry 8 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 476,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 1,525 | $2.35 | $3,583.75 |
DisclosureSEC source: 0001140361-26-008905 · form4.xml · nonDerivative · entry 7 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 474,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 2,646 | $2.83 | $7,488.18 |
DisclosureSEC source: 0001140361-26-008905 · form4.xml · nonDerivative · entry 6 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 472,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 1,250 | $4.31 | $5,387.50 |
DisclosureSEC source: 0001140361-26-008905 · form4.xml · nonDerivative · entry 5 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 470,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 2,500 | $5.00 | $12,500.00 |
DisclosureSEC source: 0001140361-26-008905 · form4.xml · nonDerivative · entry 4 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 469,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | OtherCommon Stock | 91,266 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-008905 · form4.xml · nonDerivative · entry 3 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 466,600 F2 · kind: The shares were transferred by the reporting person in accordance with the terms of a court-approved divorce settlement agreement (the "Divorce Settlement"). Read SEC document |
| March 07, 2026 Filed Mar 11, 2026 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 4,235 | $15.39 | $65,176.65 |
DisclosureSEC source: 0001140361-26-008905 · form4.xml · nonDerivative · entry 2 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 557,866 F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities. Read SEC document |
| March 06, 2026 Filed Mar 11, 2026 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 10,059 | $15.39 | $154,808.01 |
DisclosureSEC source: 0001140361-26-008905 · form4.xml · nonDerivative · entry 1 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 562,101 F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities. Read SEC document |
| February 19, 2026 Filed Feb 24, 2026 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 8,161 | $16.32 | $133,187.52 |
DisclosureSEC source: 0001140361-26-006462 · form4.xml · nonDerivative · entry 1 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 572,160 F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities. F2 · balance_after: Includes, as of the transaction date (i) 91,631 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 58,338 unvested RSUs out of 77,784 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 144,240 unvested RSUs out of 192,320 RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; F3 · balance_after: (continued from footnote 2) (iv) 15,000 unvested RSUs out of 30,000 RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; (v) 47,500 unvested RSUs out of 95,000 RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; (vi) 10,000 unvested RSUs out of 40,000 RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; F4 · balance_after: (continued from footnote 3) and (vii) 205,451 shares of common stock directly owned by the Reporting Person, which reflects prior option exercises and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 144,230 | $0.00 Strike: $16.37 | $0.00 |
DisclosureSEC source: 0001140361-26-004891 · form4.xml · derivative · entry 2 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,230 Underlying: Common Stock · 144,230 shares Expires 2036-02-09 F5 · derivative.exercise_date: The options vest over four years with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 9, 2030 in accordance with the Plan. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 91,631 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-004891 · form4.xml · nonDerivative · entry 1 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 580,321 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the Reporting Person's continued service as of the applicable vesting date. F2 · balance_after: Includes, as of the transaction date (i) 91,631 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 77,784 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 144,240 unvested RSUs out of 192,320 RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; F3 · balance_after: (continued from footnote 2) (iv) 15,000 unvested RSUs out of 30,000 RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; (v) 47,500 unvested RSUs out of 95,000 RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; (vi) 10,000 unvested RSUs out of 40,000 RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; F4 · balance_after: (continued from footnote 3) and (vii) 194,166 shares of common stock directly owned by the Reporting Person, which reflects prior option exercises and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| July 30, 2025 Filed Aug 2, 2025 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $8.98 | $0.00 |
DisclosureSEC source: 0001140361-25-028449 · form4.xml · derivative · entry 3 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2025-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted on July 30, 2015 and is fully vested. Read SEC document |
| July 30, 2025 Filed Aug 2, 2025 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 1,208 | $18.59 | $22,456.72 |
DisclosureSEC source: 0001140361-25-028449 · form4.xml · nonDerivative · entry 2 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 488,690 F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements and payment by the Reporting Person of the option exercise price. This is not an open market sale of securities. This option was automatically exercised on the expiration date. F2 · balance_after: Includes, as of the transaction date (i) 77,784 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 144,240 unvested RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 15,000 unvested RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; F3 · balance_after: (continued from footnote 2) (iv) 47,500 unvested RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (v) 10,000 unvested RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; and (vi) 194,166 shares of common stock directly owned by the reporting person, which includes the option exercise described in footnote 1 and prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| July 30, 2025 Filed Aug 2, 2025 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 2,500 | $8.98 | $22,450.00 |
DisclosureSEC source: 0001140361-25-028449 · form4.xml · nonDerivative · entry 1 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 489,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 24, 2025 Filed Jul 29, 2025 01:02 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 3,027 | $17.31 | $52,397.37 |
DisclosureSEC source: 0001140361-25-027642 · form4.xml · nonDerivative · entry 1 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 487,398 F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities. F2 · balance_after: Includes, as of the transaction date (i) 77,784 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 144,240 unvested RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 15,000 unvested RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; F3 · balance_after: (continued from footnote 2) (iv) 47,500 unvested RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (v) 10,000 unvested RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; and (vi) 192,874 shares of common stock directly owned by the reporting person, which includes the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 18,920 | $19.42 | $367,426.40 |
DisclosureSEC source: 0001140361-25-011931 · form4.xml · nonDerivative · entry 1 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 490,425 F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities. F2 · balance_after: Includes, as of the transaction date (i) 77,784 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 144,240 unvested RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 22,500 unvested RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; F3 · balance_after: (continued from footnote 2) (iv) 47,500 unvested RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (v) 10,000 unvested RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; and (vi) 188,401 shares of common stock directly owned by the reporting person, which includes the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 3,935 | $17.02 | $66,973.70 |
DisclosureSEC source: 0001140361-25-007923 · form4.xml · nonDerivative · entry 2 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 509,345 F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities. F4 · balance_after: Includes, as of the transaction date (i) 77,784 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 192,320 unvested RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 22,500 unvested RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; F5 · balance_after: (continued from footnote 4) (iv) 47,500 unvested RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (v) 10,000 unvested RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; and (vi) 159,241 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| March 06, 2025 Filed Mar 11, 2025 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 8,881 | $16.91 | $150,177.71 |
DisclosureSEC source: 0001140361-25-007923 · form4.xml · nonDerivative · entry 1 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 513,280 F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities. F2 · balance_after: Includes, as of the transaction date (i) 77,784 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 192,320 unvested RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 22,500 unvested RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iv) 47,500 unvested RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to F3 · balance_after: (continued from footnote 2) the reporting person's continued service as of the applicable vesting date; (v) 20,000 unvested RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; and (vi) 153,176 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 1,855 | $15.44 | $28,641.20 |
DisclosureSEC source: 0001140361-25-006385 · form4.xml · nonDerivative · entry 1 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 522,161 F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities. F2 · balance_after: Includes, as of the transaction date (i) 77,784 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 192,320 unvested RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 22,500 unvested RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iv) 71,250 unvested RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to F3 · balance_after: (continued from footnote 2) (v) 20,000 unvested RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; and (vi) 138,307 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| February 19, 2025 Filed Feb 22, 2025 02:01 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 116,279 | $0.00 Strike: $16.07 | $0.00 |
DisclosureSEC source: 0001140361-25-005535 · form4.xml · derivative · entry 2 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,279 Underlying: Common Stock · 116,279 shares Expires 2035-02-19 F4 · derivative.exercise_date: The options vest over four years with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 19, 2029 in accordance with the Plan. Read SEC document |
| February 19, 2025 Filed Feb 22, 2025 02:01 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 77,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-005535 · form4.xml · nonDerivative · entry 1 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 524,016 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the reporting person's continued service as of the applicable vesting date. F2 · balance_after: Includes, as of the transaction date (i) 77,784 unvested RSUs granted on February 19, 2025 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 192,320 unvested RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 22,500 unvested RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iv) 71,250 unvested RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; F3 · balance_after: (continued from footnote 2) (v) 20,000 unvested RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (vi) 5,000 unvested RSUs granted on February 25, 2021, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; and (vii) 135,162 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| January 30, 2025 Filed Feb 4, 2025 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $10.80 | $0.00 |
DisclosureSEC source: 0001140361-25-002926 · form4.xml · derivative · entry 3 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2025-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted on January 30, 2015 and is fully vested. Read SEC document |
| January 30, 2025 Filed Feb 4, 2025 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 3,355 | $16.10 | $54,015.50 |
DisclosureSEC source: 0001140361-25-002926 · form4.xml · nonDerivative · entry 2 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 446,232 F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements and payment by the Reporting Person of the option exercise price. This is not an open market sale of securities. This option was automatically exercised on the expiration date. F2 · balance_after: Includes, as of the transaction date (i) 192,320 unvested RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 22,500 unvested RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 71,250 unvested RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; F3 · balance_after: (continued from footnote 2) (iv) 20,000 unvested RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (v) 5,000 unvested RSUs granted on February 25, 2021, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; and (vi) 135,162 shares of common stock owned by the reporting person, which reflects the option exercise described in footnote 1 and prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| January 30, 2025 Filed Feb 4, 2025 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 5,000 | $10.80 | $54,000.00 |
DisclosureSEC source: 0001140361-25-002926 · form4.xml · nonDerivative · entry 1 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 449,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2024 Filed Jan 4, 2025 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 1,854 | $17.15 | $31,796.10 |
DisclosureSEC source: 0001140361-25-000271 · form4.xml · nonDerivative · entry 1 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 444,587 F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities. F2 · balance_after: Includes, as of the transaction date (i) 192,320 unvested RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 22,500 unvested RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 71,250 unvested RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; F3 · balance_after: (continued from footnote 2) (iv) 20,000 unvested RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (v) 5,000 unvested RSUs granted on February 25, 2021, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; and (vi) 133,517 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| September 30, 2024 Filed Oct 3, 2024 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 2,647 | $19.99 | $52,913.53 |
DisclosureSEC source: 0001140361-24-042642 · form4.xml · nonDerivative · entry 1 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 446,441 F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (RSUs). This is not an open market sale of securities. F2 · balance_after: Includes, as of the transaction date (i) 192,320 unvested RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 22,500 unvested RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 71,250 unvested RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; F3 · balance_after: (continued from footnote 2) (iv) 20,000 unvested RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (v) 6,250 unvested RSUs granted on September 28, 2021, which are the remaining unvested RSUs of the 100,000 RSUs granted on September 28, 2021 which vest on a schedule of 50% vesting on December 31, 2022 and the remaining vesting quarterly from March 31, 2023 to December 31, 2024, subject to the reporting person's continued service as of the applicable vesting date; (vi) 5,000 unvested RSUs granted on February 25, 2021, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; and F4 · balance_after: (continued from footnote 3) (vii) 129,121 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| August 30, 2024 Filed Aug 31, 2024 01:05 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock · Derivative | 5,000 | $4.72 Strike: $4.72 | $23,600.00 |
DisclosureSEC source: 0001140361-24-039822 · form4.xml · derivative · entry 9 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2028-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: These options were granted on May 3, 2018 and are fully vested. Read SEC document |
| August 30, 2024 Filed Aug 31, 2024 01:05 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock · Derivative | 6,650 | $5.94 Strike: $5.94 | $39,501.00 |
DisclosureSEC source: 0001140361-24-039822 · form4.xml · derivative · entry 8 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,650 shares Expires 2028-10-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: These options were granted on October 9, 2018 and are fully vested. Read SEC document |
| August 30, 2024 Filed Aug 31, 2024 01:05 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock · Derivative | 4,375 | $2.59 Strike: $2.59 | $11,331.25 |
DisclosureSEC source: 0001140361-24-039822 · form4.xml · derivative · entry 7 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,375 shares Expires 2030-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: These options were granted on March 10, 2020 and are fully vested. Read SEC document |
| August 30, 2024 Filed Aug 31, 2024 01:05 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock · Derivative | 8,125 | $2.35 Strike: $2.35 | $19,093.75 |
DisclosureSEC source: 0001140361-24-039822 · form4.xml · derivative · entry 6 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 8,125 shares Expires 2031-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options were granted on February 25, 2021 and will vest over four years with 25% of the shares of common stock underlying the options vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years thereafter, subject to the reporting person's continued service as of the applicable vesting date, and will become fully vested on February 25, 2025. Read SEC document |
| August 30, 2024 Filed Aug 31, 2024 01:05 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | SaleCommon Stock | 24,150 | $16.90 | $408,050.48 |
DisclosureSEC source: 0001140361-24-039822 · form4.xml · nonDerivative · entry 5 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 449,088 F1 · price: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $16.72 to $17.02. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes, as of the transaction date (i) 192,320 unvested RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 22,500 unvested RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 71,250 unvested RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iv) 20,000 unvested RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to F3 · balance_after: (continued from footnote 2) the reporting person's continued service as of the applicable vesting date; (v) 12,500 unvested RSUs granted on September 28, 2021, which are the remaining unvested RSUs of the 100,000 RSUs granted on September 28, 2021 which vest on a schedule of 50% vesting on December 31, 2022 and the remaining vesting quarterly from March 31, 2023 to December 31, 2024, subject to the reporting person's continued service as of the applicable vesting date; (vi) 5,000 unvested RSUs granted on February 25, 2021, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; and (vii) 125,518 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| August 30, 2024 Filed Aug 31, 2024 01:05 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 5,000 | $4.72 | $23,600.00 |
DisclosureSEC source: 0001140361-24-039822 · form4.xml · nonDerivative · entry 4 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 473,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2024 Filed Aug 31, 2024 01:05 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 6,650 | $5.94 | $39,501.00 |
DisclosureSEC source: 0001140361-24-039822 · form4.xml · nonDerivative · entry 3 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 468,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2024 Filed Aug 31, 2024 01:05 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 4,375 | $2.59 | $11,331.25 |
DisclosureSEC source: 0001140361-24-039822 · form4.xml · nonDerivative · entry 2 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 461,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2024 Filed Aug 31, 2024 01:05 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 8,125 | $2.35 | $19,093.75 |
DisclosureSEC source: 0001140361-24-039822 · form4.xml · nonDerivative · entry 1 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 457,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 24, 2024 Filed Jul 27, 2024 01:10 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 2,502 | $13.58 | $33,977.16 |
DisclosureSEC source: 0001140361-24-034472 · form4.xml · nonDerivative · entry 1 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 449,088 F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (RSUs). This is not an open market sale of securities. F2 · balance_after: Includes, as of the transaction date (i) 192,320 unvested RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 22,500 unvested RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 71,250 unvested RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; F3 · balance_after: (continued from footnote 2) (iv) 20,000 unvested RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (v) 12,500 unvested RSUs granted on September 28, 2021, which are the remaining unvested RSUs of the 100,000 RSUs granted on September 28, 2021 which vest on a schedule of 50% vesting on December 31, 2022 and the remaining vesting quarterly from March 31, 2023 to December 31, 2024, subject to the reporting person's continued service as of the applicable vesting date; (vi) 5,000 unvested RSUs granted on February 25, 2021, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; F4 · balance_after: (continued from footnote 3) and (vii) 125,518 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| June 30, 2024 Filed Jul 3, 2024 01:01 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 2,085 | $11.18 | $23,310.30 |
DisclosureSEC source: 0001140361-24-032247 · form4.xml · nonDerivative · entry 1 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 451,590 F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (RSUs). This is not an open market sale of securities. F2 · balance_after: Includes, as of the transaction date (i) 192,320 unvested RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 30,000 unvested RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 71,250 unvested RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; F3 · balance_after: (continued from footnote 2) (iv) 20,000 unvested RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (v) 12,500 unvested RSUs granted on September 28, 2021, which are the remaining unvested RSUs of the 100,000 RSUs granted on September 28, 2021 which vest on a schedule of 50% vesting on December 31, 2022 and the remaining vesting quarterly from March 31, 2023 to December 31, 2024, subject to the reporting person's continued service as of the applicable vesting date; (vi) 5,000 unvested RSUs granted on February 25, 2021, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; F4 · balance_after: (continued from footnote 3) and (vii) 120,520 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 01:01 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 300,328 | $0.00 Strike: $6.54 | $0.00 |
DisclosureSEC source: 0001140361-24-017377 · form4.xml · derivative · entry 3 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,328 Underlying: Common Stock · 300,328 shares Expires 2034-04-01 F5 · derivative.exercise_date: The option vests over four years with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on the four-year anniversary of the grant date. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 01:01 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 192,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-017377 · form4.xml · nonDerivative · entry 2 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 304,510 F3 · shares: These shares represent RSUs that will vest in four equal installments (25% per installment) on each annual anniversary of the date of grant over four years, in each case under the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan") subject to the reporting person's continued service as of the applicable vesting date. F4 · balance_after: Includes, as of the transaction date, (i) 192,320 RSUs granted on April 1, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (3); and (ii) 112,190 shares acquired pursuant to the vesting of RSUs. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 01:01 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 2,085 | $6.60 | $13,761.00 |
DisclosureSEC source: 0001140361-24-017377 · form4.xml · nonDerivative · entry 1 Kestenberg-Messina Kaitlin M. · CIK 0002017423 · COO and SVP, Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,190 F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (RSUs). This is not an open market sale of securities. F2 · balance_after: As of the transaction date, represents 112,190 shares of Common Stock acquired pursuant to the vesting of RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.